Ignite Creation Date:
2024-05-19 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06412185
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-05-09
Brief Title:
Single Dose Escalation Study of CM383 in Healthy Volunteers
Sponsor:
Keymed Biosciences CoLtd
Organization:
Keymed Biosciences CoLtd
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Phase I Clinical Study Evaluating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Immunogenicity of Single Dose Escalation of CM383 in Male Healthy Subjects
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single center randomized double-blind placebo-controlled Phase I clinical study in a single dose escalation to evaluate its safety tolerability pharmacokinetics pharmacodynamics and immunogenicity of CM383 in male healthy subjects
Detailed Description:
Alzheimers disease AD is the most common type of dementia which is a degenerative disease of the central nervous system with insidious onset and progressive development Its clinical features mainly include memory impairment cognitive impairment psychobehavioral abnormalities and social decline
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None